Furthermore, MEG3 suppresses the levels of drug-resistant transporters, including multidrug resistance-associated protein-1 (MRP1), multidrug resistance protein 1 (MDR1), and ATP binding cassette subfamily G member 2 (ABCG2), thus increasing CML cells’ sensitivity against imatinib; miR-21 mimics could reverse their levels [138]. Here, MEG3 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.